Literature DB >> 16458425

Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer.

Makoto Suzuki1, Hisayuki Shigematsu, Narayan Shivapurkar, Jyotsna Reddy, Kuniharu Miyajima, Takao Takahashi, Adi F Gazdar, Eugene P Frenkel.   

Abstract

We investigated aberrant methylation in 101 prostate cancers(PCa) and 32 histologically normal prostate tissues. We focused on genes largely in the apoptotic pathway. Methylation frequencies of the genes were Reprimo, 54%; TMS1, 47%; DcR1, 45%; RRAD, 37%; DcR2, 37%; CRBP1, 34%; HPP1, 32%; RIZ1, 31%; DRM/Gremlin, 21%; SOCS1, 20%; DR4, 5%; DR5, 1%. Methylation of Reprimo and TMS1 correlate with preoperative serum prostate-specific antigen. Methylation of TMS1, DcR1, DcR2, and CRBP1 correlate with Gleason score. Methylation of TMS1 and unmethylation of both DcR1 and DcR2 correlate with poorer disease free survival by univariate and multivariate analyses. Our data suggest that methylation of multiple genes may be involved in pathogenesis and correlate with prognosis of PCa.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458425     DOI: 10.1016/j.canlet.2005.11.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

1.  Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.

Authors:  Dan He; Yi-wang Zhang; Na-na Zhang; Lu Zhou; Jian-ning Chen; Ye Jiang; Chun-kui Shao
Journal:  Med Oncol       Date:  2015-02-27       Impact factor: 3.064

2.  Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.

Authors:  Dolly G Aguilera; Chandra M Das; Neeta D Sinnappah-Kang; Celine Joyce; Pete H Taylor; Sijin Wen; Martin Hasselblatt; Werner Paulus; Greg Fuller; Johannes E Wolff; Vidya Gopalakrishnan
Journal:  J Neurooncol       Date:  2009-01-16       Impact factor: 4.130

3.  Sensitivity of human prostate cancer cells to chemotherapeutic drugs depends on EndoG expression regulated by promoter methylation.

Authors:  Xiaoying Wang; Volodymyr Tryndyak; Eugene O Apostolov; Xiaoyan Yin; Sudhir V Shah; Igor P Pogribny; Alexei G Basnakian
Journal:  Cancer Lett       Date:  2008-06-18       Impact factor: 8.679

4.  Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.

Authors:  Li-Bo Chen; Jun-Yao Xu; Zhen Yang; Guo-Bin Wang
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

Review 5.  DNA methylation changes in prostate cancer: current developments and future clinical implementation.

Authors:  Mohammad Obaidul Hoque
Journal:  Expert Rev Mol Diagn       Date:  2009-04       Impact factor: 5.225

6.  Cisplatin-induced apoptosis and development of resistance are transcriptionally distinct processes.

Authors:  Theocharis Panaretakis
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

7.  Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.

Authors:  Yu Cheng; Jin Woo Kim; Wennuan Liu; Thomas A Dunn; Jun Luo; Matthew J Loza; Seong-Tae Kim; Siqun Lilly Zheng; Jianfeng Xu; William B Isaacs; Bao-Li Chang
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

8.  Colon cancer cell apoptosis is induced by combined exposure to the n-3 fatty acid docosahexaenoic acid and butyrate through promoter methylation.

Authors:  Youngmi Cho; Nancy D Turner; Laurie A Davidson; Robert S Chapkin; Raymond J Carroll; Joanne R Lupton
Journal:  Exp Biol Med (Maywood)       Date:  2014-02-04

9.  Expression of SOCSs in human prostate cancer and their association in prognosis.

Authors:  Jian-guo Zhu; Qi-shan Dai; Zhao-dong Han; Hui-chan He; Ru-jun Mo; Guo Chen; Yan-fei Chen; Yong-ding Wu; Sheng-bang Yang; Fu-neng Jiang; Wei-hong Chen; Zhao-lin Sun; Wei-de Zhong
Journal:  Mol Cell Biochem       Date:  2013-05-11       Impact factor: 3.396

10.  Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity.

Authors:  Mei Xu; Aaron J Knox; Katherine A Michaelis; Katja Kiseljak-Vassiliades; Bette K Kleinschmidt-DeMasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Endocrinology       Date:  2012-05-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.